Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3B, Randomized Trail of Revlimid (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Trial Profile

Phase 3B, Randomized Trail of Revlimid (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARUMM
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 13 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 05 Feb 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record. (Global end date:2020-10-12)
    • 27 Jan 2021 This trial has been completed in Greece, according to European Clinical Trials Database record. (Global end date:2020-10-12)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top